secwatch.observer — SEC 8-K summary
======================================

Issuer:     Karyopharm Therapeutics Inc. (KPTI)
CIK:        0001503802
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0001193125-24-003978
Event type: earnings
Sentiment:  positive
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Karyopharm reports preliminary FY2023 total revenue ~$146M, XPOVIO net product revenue ~$112M, meeting guidance
--------------------------------------------------------------------------------

- Full year 2023 total revenue ~$145.9M; U.S. XPOVIO net product revenue ~$112.0M; Q4 total revenue ~$33.6M.
- Cash and investments ~$192M as of Dec 31, 2023, enabling cash runway into late 2025.
- Key 2023 achievements include NCCN guideline upgrade for XVd, patent extension to Jul 2033, and ~20% workforce reduction.
- Near-term catalysts: Phase 3 readouts in 2H 2024 for multiple myeloma, enrollment completion in EC-042 for endometrial cancer, and updated myelofibrosis data.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1503802/000119312524003978/0001193125-24-003978-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1503802/000119312524003978/d86824d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-003978

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer